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Nicotine addiction is the most common serious medical problem in the country. Tobacco use is responsible for 30% of cancer deaths in the United
States and 90% of all lung cancer deaths.The physical addiction to nicotine explains why over 30% of Americans continue to smoke or use tobacco
despite their desires and efforts to quit. The testimony summarized in this paper recommends four broad strategies for preventing tobacco-caused
cancers in the United States: a) mandating and reimbursing effective treatments for nicotine addiction; b) increasing Federal and state tobacco
excise taxes and earmarking a fraction of tax revenues for tobacco prevention and cessation; c) enacting other policy changes to prevent tobacco
use and addiction among children, including expanded clean indoor air legislation, comprehensive youth tobacco access legislation, and the
regulation of tobacco products and their advertising and promotion; and d) expanding tobacco control research and critical Federal research support.
Specific recommendations are given for each broad strategy. - Environ Health Perspect 103(Suppl 8):149-152 (1995)
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Introduction
We are at a critical juncture in tobacco
control history. The nation is at the brink
of momentous changes in the health care
system and in public policy regulating the
use and marketing of tobacco products. In
fulfillment of my charge to summarize key
strategies for the prevention of tobacco-
caused cancer, I want to recommend four
basic strategies for capitalizing on these
changes and on the enormous progress we
have made in developing effective treat-
ments for nicotine addiction. These four
strategies include:. mandating and reim-
bursing treatment for nicotine addiction as
a basic preventive benefit under health care
reform; raising tobacco excise taxes sub-
stantially and using revenues wisely to sup-
port prevention and treatment programs;
enacting tough tobacco control policy to
support prevention and treatment; and
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continuing tobacco control research and
expanding research funding.
Treatment for Nicotine
Addiction
As summarized recently by McGinnis (1),
the U.S. Preventive Services Task Force has
advanced the following general criteria for
including any preventive service for cover-
age in the preventive care benefits package:
There must be evidence that the service is
efficacious and cost-effective, that using the
clinical setting for the service is necessary
or unusually advantageous, and that the
clinical setting offers special access to high-
risk populations. Treatment for tobacco
addiction meets each ofthese four criteria.
In fact, there are at least 10 good reasons
for mandating and reimbursing treatment
for nicotine addiction.
a) Nicotine addiction is the most com-
mon serious medical problem in the coun-
try today. This is because tobacco use is the
chief avoidable cause of morbidity and
mortality in the United States. It is respon-
sible for over 30% of cancer deaths in the
United States and 90% of all lung cancer
deaths (2). One in five Americans who die
each year die from tobacco use. Over 30%
ofAmericans continue to smoke or use
smokeless tobacco despite their strong
desire to quit (3).
b) Nicotine addiction, like other addic-
tions, warrants recognition and treatment
as a full-fledged addiction under health care
reform. Smoking and smokeless tobacco
use are more than bad habits. All tobacco
products contain nicotine, ahighly addictive
substance, and there is now incontrovertible
evidence, summarized in the 1988 Surgeon
General's Report (4) that nicotine addic-
tion is every bit as legitimate and serious an
addiction as heroin, cocaine, and alcohol
addiction, and just as hard to overcome.
Most of our smokers and smokeless
tobacco users want to quit, have tried, and
have failed. Young people have proven to
be just as dependent on nicotine as adults.
The most recent Surgeon General's Report
(5) shows that this addiction is clear after
100 cigarettes.
c) Another reason for including tobacco
addiction treatment in the basic benefits
package is to increase now-limited access to
effective treatment services. Past surveys have
shown that only 10 to 15% ofU.S. smokers
who try to quit receive any treatment for
nicotine addiction (6). Millions ofsmokers
have tried nicotine replacement therapies
(nicotine gum or patches) in the past 10
years, but few have received the adjuvant
therapy needed to make these pharmacologic
treatments work (7). Financial barriers are
the key to underutilization. Treatment has
been the least accessible to Americans with
the lowest income, the least education, and
minority/racial ethnic status. These are the
groups, as we have seen, with the greatest
prevalence oftobacco use and the greatest
burden oftobacco-caused cancer.
d) Do we have effective treatments to
offer? Absolutely. Two decades ofchiefly
National Institutes ofHealth (NIH)-funded
biobehavioral research have produced a
range ofeffective treatments for nicotine
addiction. The greatest progress has been
made in the development ofwidely accept-
able, easily disseminated, low-intensity,
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low-cost treatments that now produce 15
to 20% 1-year quit rates. These treatments
are increasingly tailored to special popula-
tions, including pregnant smokers, African
American and Latino smokers, and athletes
who use smokeless tobacco (8). We have
found that adding briefpersonalized coun-
seling (face-to-face, by phone, or by mail)
to self-help materials raises quit rates to the
25 to 30% level. These are quit rates that
most clinics achieve, although clinics are
far less acceptable to smokers (8,9). In
addition, we have made enormous progress
in developing stage-based treatments that
are suitable for smokers who are not yet
ready to quit, including the use of bio-
marker feedback to raise quitting motivation
(10). And, finally, nicotine replacement
therapy has been found to boost these self-
help and clinic treatment outcomes by
100% to 300%, so that 50% quit rates are
now conceivable. This is phenomenal
progress. Ifwe had cure rates like this for
other chronic diseases, for which treatment
generally is reimbursed, we would be a
much healthier nation.
e) Treating nicotine addiction in med-
ical settings does have powerful advantages.
The doctor-patient relationship provides a
unique and powerful context for nicotine
addiction treatment. And, most American
smokers who quit do so for health reasons.
In research summarized by Glynn and
Manley (11), based on over 30,000 smok-
ers and over 1000 providers (mostly physi-
cians and dentists), smokers who received
brief physician-assisted treatment during
regular medical care (often a matter of
3-5 min) were 2 to 6 times more likely to
quit than smokers receiving usual care. The
most successful physician-assisted treat-
ments used multiple modalities, a combi-
nation of face-to-face advice, printed
materials, and pharmacologic evidence,
and involved repeated contacts over a num-
ber ofhealth care visits and a team approach
(12). This is not a one-shot intervention. It
is not particularly cosdy or labor-intensive,
but it must be continuous over repeated
health care episodes. And, I think, for that
reason, it must be mandated and sup-
ported. Today, only halfofAmericans say
they have ever received even physician
advice to quit (13).
Moreover, effective treatment models
have been defined for a range ofnonphysi-
cian providers-psychologists, dentists,
nurses, respiratory therapists, and certified
addiction counselors. Tobacco intervention
certification and training programs are
reaching greater numbers of American
health care providers than ever before.
Finally, the Joint Commission for Accredi-
tation of Health Care Organizations
JCAHO) now bans all patient smoking in
accredited hospitals, providing unprece-
dented opportunities to reach hospitalized
smokers who may be most at risk for
tobacco-caused cancer. Only a dozen hos-
pitals in the United States offer any form
of inpatient treatment program, however,
and again, reimbursement is a chiefbarrier.
f) Is treating nicotine addiction cost
effective? Yes. Eddy (14) has called it "the
gold standard" ofprevention cost effective-
ness. It requires less cost per year of life
saved than most preventive screening ser-
vices or the treatment ofhypertension or
hypercholesterolemia (15,16). New data
show that hospital-based smoking cessation
treatments for heart attack survivors are
up to 200 times more cost effective than
commonly reimbursed medical care (17).
g) Science-based clinical practice guide-
lines are currently under development by
the newly formed Agency for Health Care
Policy and Research (AHCPR) panel on
Smoking Cessation and Prevention. These
guidelines will give us a critical tool to
move toward mandated treatment. They are
likely to outline cost-effective stepped-care
treatment models with patient-treatment
matching (13,18).
h) The potential to deliver nicotine
addiction treatments through public and
private health care delivery systems has
never been greater than it will be over the
next decade, in large part because ofwide
implementation of the National Cancer
Institute's (NCI's) ASSIST and Centers for
Disease Control and Prevention's (CDC's)
IMPACT Statewide programs, the wide
reach ofthe NCI's Train the Trainer pro-
gram, and the growth of pharmacologic
therapies, especially nicotine replacement
therapies, which have involved more physi-
cians and pharmacists more directly in the
treatment process (8,18).
i) Health care reform will improve the
infrastructure and incentives for equitable
and cost-effective nicotine addiction treat-
ment, not only through wider prevention
programming and universal access but also
because it will involve a shift toward health
plans that provide care through integrated
networks ofservices and providers, which
will result in greater continuity ofcare over
time and providers. These conditions will
help to facilitate repeated tobacco interven-
tions over time and health care visits (12).
Health care reform will also fuel greater use
ofsophisticated information systems and
interactive computer-based programs that
can be harnessed to create and deliver highly
personalized quitting messages and support
programs thatdo not burden providers (13).
j) Finally, increased Federal excise taxes
can provide the revenues needed to treat
nicotine addiction, as we have seen in
California and Massachusetts (19). In both
states, a fraction ofexcise tax revenues were
earmarked for prevention and treatment.
Tobacco Excise Taxes Are
Keyto Funding Health Care
Reform and Tobacco Control
Tobacco is the single most appropriate
source ofrevenue for health care reform. It
is the only product that causes addiction,
disease, and death when used as intended.
It is responsible for 419,000 deaths each
year and costs the nation $68 billion yearly
in health care costs and lost productivity.
The increased Federal tobacco excise taxes
now being debated will generate 30 to $60
billion in revenues over a 3-year period,
and recent polls have found that two-thirds
ofvoters-smokers and nonsmokers alike-
favor a $2 per pack tobacco excise tax to
generate revenues for health care and health
care reform (20). Moreover, substantially
raising the Federal excise taxes on all tobacco
products, cigarettes, and smokeless tobacco,
will propel tens of thousands of the
nation's 49 million smokers (2-4) and 12
million smokeless tobacco users (4-6) to
quit and dramatically curb youth initiation
ofsmoking and smokeless tobacco use.
Almost all new users oftobacco are chil-
dren (20). As last year's Surgeon General's
Report summarizes, over 90% ofall smok-
ers start when they are children or teen-
agers. Most start before age 16. Today, 3.1
million adolescents, including 25% of all
17- and 18-year-olds, are smokers, and 3
million children and teens use smokeless
tobacco-today's "stealth tobacco"-fore-
boding a new oral cancer epidemic (5). In
the United States, there has been no signifi-
cant decline in youth smoking since the
early 1980's. However, during roughly the
same period (from 1980 to 1991), youth
smoking dropped 60% in Canada, where
tobacco taxes were raised by60% (21).
A $2 per pack tax will be far more
effective than a $0.75 tax, and we must not
let the tobacco industry lobby Congress
out of it. A $2 tax could save 1 million
more lives and generate far more revenue
than a $0.75 tax (20). Today, the United
States ranks nineteenth among 19 devel-
oped countries in the magnitude of our
excise tax. A $2 tax would raise our rank to
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9th (5). But make no mistake; it is not
enough just to raise tobacco excise taxes. A
fraction ofthose taxes, even just 2 to 5%,
must be earmarked for tobacco control. As
the NCI's Expert Panel on Tobacco
Taxation concluded, "raising excise taxes is
most effective when part ofa comprehensive
tobacco control program that includes other
policy interventions, mass media counter-
advertising, public education, school-based
prevention programs, and help for smokers
who want to stop" (21).
California's Proposition 99 and Mass-
achusetts' similar state initiative provide
models for the comprehensive tobacco con-
trol programs advised. Each state earmarks
a portion of its state tobacco excise tax
increases for tobacco prevention and cessa-
tion programs. Results from California
indicate that a modest ($0.25) tobacco tax
increase alone is unlikely to have dramatic
effects on youth smoking in the absence
of such comprehensive tobacco control
programming (19).
Tax revenues must be earmarked for
cessation as well as prevention programs.
There are two reasons for this. First, devot-
ing some portion oftobacco tax revenues to
the treatment ofnicotine addiction makes
the tax less exploitative and responds to
critics of the tax's regressivity. Second,
tobacco tax revenues must be tied to needs
that will decline with a decline in tobacco
use to prevent excessive tobacco tax depen-
dence. David Dangoor, Executive Vice
President of Philip Morris International,
was quoted in the New York Times
Magazine as saying, "We have the best part-
ners in the world: the governments. In a lot
of countries, it's incredibly important to
the whole welfare state that we sell our
products to collect taxes." (22). We must
act to reduce our long-term dependence on
tobacco tax revenues for uses other than
prevention, cessation, and health care for
tobacco-caused disease.
Policy Needed to Support
Prevention, Treatment
Besides increasing tobacco excise taxes,
other policy changes are also essential. The
primary conclusion of the 1994 Surgeon
General's Report is that policy initiatives
are our strongest tools for curbing smoking
and tobacco use initiation in childhood
and adolescence (5). Four major powerful
policy initiatives get special attention.
Clean Indoor Air legislation is essential to
protect nonsmokers from the proven dan-
gers ofenvironmental tobacco smoke (ETS),
now classified as a Type A carcinogen. The
Smoke-Free Environment Act proposed by
the House Subcommittee on Health and
the Environment exemplifies this type of
legislation; it would restrict or ban smok-
ing in all public places used by more than
10 people. We also need comprehensive
youth tobacco access legislation; for exam-
ple, the Synar Amendment, which requires
state retailer licensing, unannounced
inspections, penalties for violations, and
bans on vending machines, free samples,
and the sale of "loosies" (single cigarettes).
The 1994 Surgeon General's Report (5)
also emphasizes the need to regulate tobacco
advertising and promotion, citing grow-
ing evidence that children and teens are
especially susceptible to this advertising.
This core policy agenda includes the
1994 Surgeon General's Report (5) recom-
mendation that tobacco be included in
school-based drug prevention curricula and
that we implement school-based tobacco
use prevention programs that have com-
munity-wide support. Recent evidence that
cigarette manufacturers may carefully
titrate cigarettes' nicotine levels has given
the Food and Drug Administration new
impetus to push for regulation ofotherwise
unregulated tobacco products. These rec-
ommendations are also included in the pol-
icy initiatives recommended by the 1994
Surgeon General's Report on Preventing
Tobacco UseAmongYoung People (5).
Control Research and
Research Funding Must
Be Expanded
The fourth and final strategy for preventing
tobacco-caused cancer is to continue to
fund innovative biobehavioral tobacco con-
trol research and expand the revenues avail-
able for it. Some ofthe many critical areas
needing further research to help answer
still unanswered questions about the etiol-
ogy oftobacco use and addiction, develop
and test preventive programs and policy
initiatives, and come up with breakthrough
treatments are
* Neurobiologic effects ofearly nicotine
exposures
* Etiology oftobacco use-especially dis-
tal factors
* Better patient-treatment matching
* Women's special tobacco risks/treat-
ments-across lifespan
* Tailored treatments for special popula-
tions (minorities, teens, women, heavy
smokers) and medically high-risk
groups, including pregnant smokers
* Treatments for smokeless tobacco
addiction
* Validation of continuous (vs dichoto-
mous) outcome measure to drive down
research sample sizes/costs and facilitate
discovery ofbreakthrough treatments
* Postmarketing assessment of nicotine
therapies, including long-term nicotine
replacement
* Cost-effectiveness treatment research
* Tobacco policy research.
In addition, our efforts to expand
research support should include
* Earmarking some excise tax revenues
for research
* Including nicotine addiction in OSAP's
research efforts
* Establishing a standing NIH review
group/study section on tobacco
use/addiction.
We must learn more about the etiology
oftobacco use, including the role ofearly
(even fetal) nicotine exposure and genetic
factors. Lung cancer is now the leading
cause ofcancer death among women in the
United States (2). Women's special tobacco
risks across the lifespan need further study,
especially given new evidence that women
smokers may be more susceptible to lung
cancer. Gritz and Moon (23) have proposed
a new model for cancer prevention and con-
trol that uses biomarkers and intermediate
end points to guide patient-treatment
matching. Research to test its application to
smoking and tobacco use is greatly needed.
Special research among minority popu-
lations is also needed, especially given new
evidence for racial differences in the mecha-
nisms of tobacco addiction and carcino-
genesis, and the continued high rates of
smoking within U.S. minority populations
(African Americans, Latinos, Asian Ameri-
cans, Native Americans) (3). In general, we
need more research to identify effective,
tailored treatments for special popula-
tions-women, minorities, teens, and
heavy smokers-and medically high-risk
groups such as pregnant smokers. There is
still much to be learned as well about
effective treatments for smokeless tobacco
addiction for youth and for adults. To
the treatment research list, I would add
recommendations for postmarketing
assessments of nicotine replacement thera-
pies, sorely needed cost-effectiveness treat-
ment research, and efforts to develop
useful continuous (vs dichotomous) treat-
ment outcome measures, measures that
would permit us to move to much smaller
sample sizes for early-stage research testing
of innovative new treatments. Tobacco
policy research and studies to improve
the impact of school-based prevention
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programs also are critical for our progress
in the prevention arena.
The sad reality is that tobacco interven-
tion research funds currently are limited and
are likely to shrink even further. We must
expand the funds available for research to
conquer the nation's most deadly addiction.
Earmarking federal excise tax revenues for
research would be a big help. A 1% research
reserve would yield 3.6 to $5.9 billion over
the next 3 years (based on a per pack
Federal excise tax from 0.75 to $2). As rec-
ommended in the recent American Medical
Association summit on tobacco (24), I
would also recommend including nicotine
addiction in the Office for Substance Abuse
Prevention's (OSAP's) research efforts and
establishing a standing review group or
study section on tobacco use and addiction
at the National Institutes ofHealth.
In conclusion, the last decade ofresearch,
advocacy, and policy advances place us in a
better position than we have ever been to
prevent and control tobacco use and
tobacco-caused disease. We have the oppor-
tunity and obligation to lead the world in
the fight against tobacco and tobacco-caused
cancer. Also, however, we've never had so
great a lead to squander. Let's not miss this
precious chance.
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